Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody

There is no doubt that COVID-19 outbreak is currently the biggest public health threat, which has caused catastrophic consequences in many countries and regions. As host immunity is key to fighting against virus infection, it is important to characterize the immunologic changes in the COVID-19 patients, and to explore potential therapeutic candidates. The most efficient ways to end this pandemic are to vaccinate the susceptible population, and to use specific drugs, such as monoclonal antibodies against the viral spike protein (S protein), to treat the affected individuals. Several promising neutralizing antibodies have recently been reported (Cao et al., 2020; Lv et al., 2020). However, no antibody drug against COVID-19 has been approved yet in the world. Against the rapidly evolving SARS-CoV-2 virus, a cocktail of several non-competing antibodies may reach to the maximum treatment effect (Cai et al., 2020). Therefore, developing new potential antibodies remain be highly valuable.

Early-stage recovery patients maintain various immune responses and possess abundant protective antibodies in the circulation (Thevarajan et al., 2020). Therefore, we conducted a joint analysis using single cell transcriptome sequencing (scRNA-seq), single cell BCR sequencing (scBCR-seq) and deep BCR repertoire profiling to prioritize the therapeutically relevant neutralizing antibody sequences in patients who have recently cleared the virus.

Fresh blood samples were collected from a total of 16 COVID-19 patients at the time of hospital discharge (Table S1 and Supplementary Materials). PBMCs were divided into three aliquots for separate data generation: 1) single cell RNA sequencing, 2) single cell BCR V(D)J sequencing and 3) deep BCR repertoire sequencing (Fig. 1A and Table S1). In total, we obtained single cell 5′V(D)J sequencing data from 88,974 immune cells (Table S2) and immune receptor hypervariable regions from 6.9 million BCR clones (Table S3).

Figure 1

Identification of clonally expanded BCR groups and neutralizing antibodies. (A) Overview of experimental design. PBMC samples from recovered COVID-19 patients at discharge were collected and simultaneously performed single cell RNA-seq with 5′VDJ capture and deep B cell repertoire sequencing. (B) UMAP map of B cells from twelve COVID-19 patients and eight healthy controls, which formed a gradient of transcriptional states from naïve B cells to an activated memory B cells then to plasma cells. (C) Barplot showing the percentages for different B cell subgroups identified from single cell analysis, including naïve B cell (C10), resting memory B cells (C16), activated B cells (C24) and plasma cells (C27). Error bar labels one standard deviation of the data. Statistical significance was estimated using two-sided Wilcoxon rank sum test. ns, P > 0.05. (D) BCR diversity compared between patients and a control cohort of 235 deep BCR-seq samples. The diversity was measured using D50, which is proven robust to sequencing library size. P value was estimated using two-sided Wilcoxon test. (E) Pie chart showing the percentage of the 9 different Ig heavy chain isotypes of COVID-19 patients and healthy controls. Numbers in the parentheses are the averaged percentage of the corresponding Ig isotype across all the individuals, calculated using deep BCR-seq data. (F). UMAP plot shows the 347 potential antigen-specific BCRs are enriched in activated B cells (C24) and plasma cells (C27). (G) Lineage tree of selected BCRs heavy chain groups, with aligned DNA sequences as reference on the right. Different nucleotides are labeled with different colors, with translational frame marked beneath each plot. Each node represents a BCR clone, with color indicating the Ig isotype. The size of node reflects the frequency (in read counts) of the clone. (H) Competition binding to the COVID-19 virus RBD between antibody GD1-68 and GD1-69 and ACE2. X-axis represented the concentration of these two antibodies and Y-axis stood for percentage of uninterrupted RBD/ACE2 interaction. IC50, half-maximum inhibitory concentration. (I) The neutralization potency of GD1-69 was determined by pseudovirus-based neutralization assay. The mixtures of SARS-CoV-2 pseudovirus and serially diluted antibodies were added to HEK293T cells stably overexpressing human ACE2 (293T-ACE2 cells). IC50 values were calculated by fitting the cytopathic effect from serially diluted antibody to a sigmoidal dose-response curve. (J) The neutralization activity of the antibody GD1-69 was performed using a plaque reduction neutralization test assay. Serial dilutions of GD1-69 were incubated with SARS-CoV-2, and then added to pre-plated Vero E6 cell monolayers. The cells were incubated for 48 h with agarose overlay. Neutralizing titers (IC50 values) were calculated as the maximum antibody dilution yielding a 50% reduction in the number of plaques relative to that for control IgG protein

To reveal the changes of immune cells caused by SARS-CoV-2 infection, 8 healthy controls with single cell transcriptome data profiled by 10x Genomics were added in this study (Table S2 and Supplementary Materials). In total, we obtained 130,547 immune cells, comprising 88,974 cells (mean: 7,414 cells) for COVID-19 patients and 41,573 cells (mean: 5,196 cells) for healthy controls. Using unsupervised clustering, we found 28 distinct clusters representing different cell types (Fig. S1A), and identified the major PBMC cell types, including monocytes (C3, C4, C5, C6, C7, C12, C14, C19, C21, C22 clusters) with CD14, CD68 and CD163 expression; conventional CD4+ T cells (C1, C3, C8, C20 clusters); cytotoxic CD8+ T cells (C11, C15, C17, C18, C25, C26 clusters) which express CD8, CCL5, NKG7, GNLY; NK cells (C2 and C9 clusters) characterized by KLRD1 (CD94), KLRB1 (CD161), NCR1 (CD335) expression; and B cells (C10, C16, C24 clusters) with CD79, MS4A1 (CD20), BANK1 expression (Fig. S1B). We also found 3 other clusters, annotated as regulatory CD4+ T cells (C23 cluster) with FOXP3, CTLA4 (CD152) and IL2RA expression; plasma cells (C27 cluster) expressing CD38 and TNFRSF17 (CD269), and CD1C+CD1E+ dendritic cells (C28 cluster) (Fig. S1B). Cells were manually annotated by assessing the expression of classic marker genes and their expression similarity with purified bulk RNA-seq datasets.

Next, we focused our research on B cells (C10, C16, C24 and C27 clusters). We observed that B cells formed a gradient of transcriptional states from naïve B cells to an activated memory B cells then to plasma cells (Fig. 1B). We then compared the abundance of different B cell clusters between COVID-19 patients and controls, and observed average of 3.1 folds increase of plasma cells (C27 cluster) in the patients compared to healthy controls (Fig. 1C). In addition, we collected deep BCR-seq data from 235 additional healthy donors (Supplementary Materials). Compared to healthy individuals, COVID-19 patients showed significantly lower BCR diversity (Fig. 1D), indicating widespread B cell clonal expansions upon likely antigen recognition. With deep BCR sequencing, we investigated immunoglobulin (Ig) heavy chain isotypes for patients and controls. While in both cohorts, IgM presents the largest fraction in the peripheral repertoire, significantly higher abundance of IgG1 (P = 3.6 × 10−7, Wilcoxon test) and IgA1 (P < 2.2 × 10−16) antibodies were observed in COVID-19 patients (Fig. 1E). These changes are consistent with the anti-viral responses mounted by the adaptive immune system to clear viral particles in the blood and lung mucosa (Palladino et al., 1995). Antigen experienced B cells undergo somatic hypermutations (SHM) and Ig class switch recombination (CSR) to produce high-affinity antibodies and persistent protection (Gitlin et al., 2016).

We clustered similar heavy chain CDR3s to identify expanded B cell clonotypes, an approach proven effective to isolate antigen-specific antibodies (Hu et al., 2019). The screening process is shown in Fig. S2. We assembled a total of 74,634 BCR groups from all 16 COVID-19 patients, with each group representing a potential B cell clonal expansion event. Ig CSRs were determined based on the presence of different isotypes within each group. Consistently, we observed significantly enriched IgM to IgA1 or IgG1 events in most patients (Fig. S3). This analysis also allowed joint use of SHM and CSR to track the BCR evolution upon antigen stimulation. We identified a number of groups stemmed from naïve IgM B cells that sequentially acquired mutations in a focused region of the CDR3 loop (Zou et al., 2015), and ultimately evolved into IgA1 or IgG1 B cells (Figs. 1G and S4). The frequencies of the terminal clones are orders of magnitude than their ancestor IgM cells. In addition, when mapped to the scRNA-seq data, the expanded BCRs are enriched in activated B cells (C24) and plasma cells (Fig. 1F), corroborating their role in anti-viral responses.

Following the above results, we chose 347 BCR groups (Table S4) with highest potential to be antigen-specific using SHM and CSR as selection criteria (Supplementary Materials). In order to find potential high affinity antibodies, we kept the BCR heavy chain with the highest gene expression from single-cell BCR-seq in each BCR group, and then paired them with the corresponding light chain in single-cell BCR data to obtain a complete antibody sequence. Finally, we obtained 347 natural antibodies that were highly expanded in the patient's blood with evidence of antigen selection. In order to study the efficacy of these candidate antibodies, 100 antibodies were randomly selected for in vitro verification (Fig. S2 and Supplementary Materials). For each antibody, the DNA plasmids containing paired Ig heavy and light chains were synthesized, and transfected into HEK-293T cell line for antibody production. After purification, the antibodies were tested for the binding to the whole S protein, and the receptor-binding domain (RBD) of S protein using enzyme-linked immunosorbent assay (ELISA), respectively. 14 antibodies had strong binding to S protein (Table S5), and 3 of them (GD1-68, GD1-69 and GD1-75) had obvious binding to RBD, which may be neutralizing antibodies with clinical value. Among them, we found that GD1-69 has the highest binding affinity, with half-maximum inhibitory concentration IC50 = 0.26 μg/mL (Fig. 1H). The neutralization activity of the GD1-69 was further confirmed by pseudovirus-based neutralization assays with IC50 value of 1.77 μg/mL (Fig. 1I). To evaluate its neutralization potential against the authentic virus, we performed the plaque reduction neutralization test assay in Vero E6 cells using GD1-69 and live SARS-CoV-2 virus isolated from COVID-19 patients (Wang et al., 2020; Wu et al., 2020). GD1-69 showed viral inhibition with an IC50 of 0.44 μg/mL (Fig. 1J). Together, our data have shown that highly potent neutralizing monoclonal antibodies could be identified from early recovered patients by high-throughput single cell 5’V(D)J sequencing and bulk BCR repertoire sequencing.

So far, tens of millions of people have been infected by SARS-CoV-2, resulting in hundreds of thousands of deaths worldwide. SARS-CoV-2 neutralizing monoclonal antibodies are the most effective method for the treatment of infected patients. The joint use of scRNA-seq and deep repertoire profiling provided us the resolution of single cells, and also allowed us to acquire potential neutralizing antibodies. Using an ultrafast clustering algorithm, we uncovered over 74K expanding BCR groups out of 6 million sequences, each group bearing the evidence of recent antigen exposure and selection, i.e., somatic hypermutations and/or Ig class switch recombination. We identified 14 novel antibodies binding to S protein, and GD1-69 has the highest neutralizing activity. Currently there is a growing consensus that a combination of different, non-competing antibodies (Cai et al., 2020), or a “cocktail”, may reach to the optimum anti-viral effects, and our report had provided an additional promising reagent to the future medicines against the rapidly evolving SARS-CoV-2 virus.

Taken together, our study provides a valuable SARS-CoV-2 neutralizing monoclonal antibody named GD1-69. We anticipate future multidisciplinary efforts to carry forward the findings in our work to alleviate the ongoing crisis caused by the COVID-19 pandemic.


  1. Cai J, Sun W, Huang J, Gamber M, Wu J, He G (2020) Indirect virus transmission in cluster of COVID-19 cases, Wenzhou, China, 2020. Emerg Infect Dis J 26(6):1343–1345

    CAS  Article  Google Scholar 

  2. Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng C et al (2020) Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell 182:73-84.e16

    CAS  Article  Google Scholar 

  3. Gitlin AD, von Boehmer L, Gazumyan A, Shulman Z, Oliveira TY, Nussenzweig MC (2016) Independent roles of switching and hypermutation in the development and persistence of B lymphocyte memory. Immunity 44:769–781

    CAS  Article  Google Scholar 

  4. Hu X, Zhang J, Wang J, Fu J, Li T, Zheng X, Wang B, Gu S, Jiang P, Fan J et al (2019) Landscape of B cell immunity and related immune evasion in human cancers. Nat Genet 51:560–567

    CAS  Article  Google Scholar 

  5. Lv Z, Deng Y-Q, Ye Q, Cao L, Sun C-Y, Fan C, Huang W, Sun S, Sun Y, Zhu L et al (2020) Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody. Science 369:1505–1509

    CAS  Article  Google Scholar 

  6. Palladino G, Mozdzanowska K, Washko G, Gerhard W (1995) Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol 69:2075–2081

    CAS  Article  Google Scholar 

  7. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, Jia X, Nicholson S, Catton M, Cowie B et al (2020) Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 26:453–455

    CAS  Article  Google Scholar 

  8. Wang J, Shuai L, Wang C, Liu R, He X, Zhang X, Sun Z, Shan D, Ge J, Wang X et al (2020) Mouse-adapted SARS-CoV-2 replicates efficiently in the upper and lower respiratory tract of BALB/c and C57BL/6J mice. Protein Cell 11(10):1–7

    CAS  Article  Google Scholar 

  9. Wu S, Zhong G, Zhang J, Shuai L, Zhang Z, Wen Z, Wang B, Zhao Z, Song X, Chen Y et al (2020) A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat Commun 11:4081

    CAS  Article  Google Scholar 

  10. Zou Q, Hu Q, Guo M, Wang G (2015) HAlign: fast multiple similar DNA/RNA sequence alignment based on the centre star strategy. Bioinformatics 31:2475–2481

    CAS  Article  Google Scholar 

Download references


We thank the patients who took part in this study. This work was funded by the National Natural Science Foundation of China (Nos. 61822108, 62041102 and 62032007 to Q.J.), and the Emergency Research Project for COVID-19 of Harbin Institute of Technology (No. 2020-001 to Q.J.) and the Scientific Research Project Approved by Heilongjiang Provincial Health Committee (No. 2019-253 to J.L.).

Q.J. and Z.B. conceived the project. J.W. and J.L. collected the blood samples. F.L. and R.L. isolated PBMC cells, extracted RNA and DNA, performed neutralization assay. Q.J., P.W., M.L., W.Z., X.J., Z.X., L.J., Z.Z., Y.L., Y.L., C.X., K.M. and H.C. contributed to data analysis. Q.J. and P.W. wrote the manuscript.

Fang Li, Meng Luo, Wenyang Zhou, Jinliang Li, Xiyun Jin, Zhaochun Xu, Liran Juan, Zheng Zhang, Yuou Li, Renqiang Liu, Yiqun Li, Chang Xu, Kexin Ma, Huimin Cao, Jingwei Wang, Pingping Wang, Zhigao Bu and Qinghua Jiang declare that they have no conflict of interest. All procedures followed were in accordance with the Ethical Standards of the Responsible Committee on Human Experimentation (Institutional and National) and with the Helsinki Declaration of 1975, as revised in 2000(5). Informed consent was obtained from the patients and this study was approved by the Ethics Committee in the Harbin Sixth Hospital (Approval Number 2020NO.12). All experiments with infectious SARS-CoV-2 were performed in the biosafety level 4 facilities in the Harbin Veterinary Research Institute (HVRI) of the Chinese Academy of Agricultural Sciences (CAAS), which is approved for such use by the Ministry of Agriculture and Rural Affairs of China. All single-cell RNA sequencing data have been deposited in the zenodo under accession URL

Author information



Corresponding authors

Correspondence to Pingping Wang or Zhigao Bu or Qinghua Jiang.

Electronic supplementary material

Below is the link to the electronic supplementary material.

(PDF 1368 kb)

(XLSX 11 kb)

(XLSX 12 kb)

(XLSX 11 kb)

(XLSX 113 kb)

(XLSX 18 kb)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Li, F., Luo, M., Zhou, W. et al. Single cell RNA and immune repertoire profiling of COVID-19 patients reveal novel neutralizing antibody. Protein Cell (2020).

Download citation